SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eiger BioPharmaceuticals, Inc.
globenewswire.com
news
2022-10-15 00:00:00

NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eiger BioPharmaceuticals, Inc. (''Eiger' or the 'Company') (NASDAQ: EIGR).   Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Eiger and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 6, 2022, Eiger issued a press release 'provid[ing] an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications with the U.
